Abstracts tagged "COVID-19"

Abstract Number: L09 • ACR Convergence 2021
A Prediction Model to Distinguish Patients with Multisystem Inflammatory Syndrome in Children
Matthew Clark¹, Danielle Rankin², Alisa Gotte¹, Alison Herndon¹, William McEachern¹, Andrew Smith³, Daniel Clark¹, Edward Hardison¹, Anna Patrick¹, Lauren Peetluk¹, Natasha Halasa¹, James Connelly¹ and Sophie Katz¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³The Heart Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a rare consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MIS-C shares features with common infectious and…
Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Jasvinder Singh¹, Namrata Singh², Alfred Anzalone³, Amy Olex⁴, Jing Sun⁵, Vithal Madhira⁶ and Rena Patel⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Washington, Bellevue, WA, ³University of Nebraska, Omaha, NE, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Johns Hopkins University, Baltimore, MD, ⁶Palila Software, Reno, NV, ⁷Unviersity of Washington, Seattle, WA
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
Abstract Number: L17 • ACR Convergence 2021
Additional Heterologous versus Homologous Booster Vaccination in Immunosuppressed Patients Without SARS-CoV-2 Antibody Seroconversion After Primary mRNA Vaccination: A Randomized Controlled Trial
Michael Bonelli¹, Daniel Mrak¹, Selma Tobudic¹, Daniela sieghart¹, Peter Mandl¹, barbara kornek¹, elisabeth simader¹, Maximilian Koblischke¹, Helga Radner¹, thomas perkmann¹, helmuth haslacher¹, Margareta Mayer¹, philipp hofer¹, Kurt Redlich², Emma Husar-Memmer³, Ruth Fritsch-Stork⁴, Renate Thalhammer¹, Karin Stiasny¹, Stefan Winkler¹, Josef Smolen¹, Judith Aberle¹, Markus Zeitlinger¹, Leonhard Heinz¹ and Daniel Aletaha⁵, ¹Medical University of Vienna, Vienna, Austria, ²Hietzing Hospital, Vienna, Austria, ³Hanusch Hospital, Vienna, Austria, ⁴Sigmund Freud University, Utrecht, Netherlands, ⁵Medical University Vienna, Wien, Austria
Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond to…
Abstract Number: L18 • ACR Convergence 2021
Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study
Satveer K Mahil¹, Katie Bechman², Antony Raharja¹, Clara Domingo-Vila³, David Baudry¹, Matt Brown², Andrew Cope², Tejus Dasandi¹, Hataf Khan⁴, Thomas Lechmere⁴, Michael Malim⁴, Freya Meynell¹, Emily Pollock³, Kamila Sychowska³, Jonathan Barker¹, Sam Norton⁵, James Galloway², Katie Doores⁴, Timothy Tree³ and Catherine Smith¹, ¹St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, ²Centre for Rheumatic Diseases, King's College London, London, ³Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom, ⁴Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom, ⁵Psychology Department, Institute for Psychiatry Psychology & Neuroscience, King’s College London, London
Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains limited. Our cohort…
Abstract Number: 0095 • ACR Convergence 2021
Risk Factors for “Long Haul” COVID-19 in Rheumatology Outpatients in New York City
Medha Barbhaiya¹, Deanna Jannat-Khah¹, Jonah Levine¹, Huong Do¹, Jessica Gordon¹, Vivian Bykerk² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: COVID-19 ‘long-haulers’ are individuals who experience persistent symptoms after COVID-19 diagnosis. Whether this is of particular concern for rheumatic disease patients, due to their…
Abstract Number: 0113 • ACR Convergence 2021
Reactogenicity of the SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease
Monica Yang¹, Kimberly E. Taylor¹, Diana Paez¹, Alex Carividi¹, Emanuel Demissie¹, Niti Pawar¹, Alia A. El-Qunni,², Lily E. McMorrow², Rebecca E. Schriefer², Katherine Huang², Baylee Kinnett², Wooseob Kim², Ali H Ellebedy², Matthew Ciorba², Michael Paley³, Parakkal Deepak², Alfred Kim², Patricia Katz¹, Mehrdad Matloubian¹, Mary Nakamura⁴ and Lianne Gensler⁵, ¹University of California San Francisco, San Francisco, CA, ²Washington University School of Medicine, St. Louis, MO, ³Washington University in St. Louis, Olivette, MO, ⁴UCSF/SFVAHCS, San Francisco, CA, ⁵Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Little is known about the reactogenicity and related SARS-CoV-2 vaccine response in patients with chronic inflammatory disease (CID). While researchers have hypothesized increased symptomatology…
Abstract Number: 0501 • ACR Convergence 2021
Immunogenicity of a Single Dose of Covid-19 Vaccination in Patients with Systemic Sclerosis with or Without Immunosupression
Vishal Kakkar¹, Rebecca Ross², Ranjitha Karanth³, Sumit Lahiri⁴, Panji Mulipa¹, Pamela Hughes⁵, Brendan Clarke⁵, Clive Carter⁵, Mark Lobb⁵, Sinisa Savic⁶ and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²LIRMM University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, LTHT, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Transplant and Cellular Immunology, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is a rare connective tissue disease with multi-systemic involvement, which at times requires the use of immunosuppressive medication. None of the…
Abstract Number: 0886 • ACR Convergence 2021
Determinants of Accessing Social and News Media and Experiencing Negative Impacts During COVID-19 in an International SLE Sample
Francesca Cardwell¹, Susan Elliott², Ricky Chin³, Leigha Rowbottom⁴, Yvan St.Pierre⁵, May Choi³, Murray Urowitz⁶, Guillermo Ruiz-Irastorza⁷, Sasha Bernatsky⁸, Michelle Petri⁹, Susan Manzi¹⁰, Christine Peschken¹¹, Rosalind Ramsey-Goldman¹², Paul R Fortin¹³, Jungmin Shin¹⁴, Sang-Cheol Bae¹⁵, Jiacai Cho¹⁶, Anselm Mak¹⁷, John Hanly¹⁸, Anca Askanase¹⁹, Juanita Romero-Diaz²⁰, Romina Nieto²¹, Bernardo A. Pons-Estel²², Ian N. Bruce²³, Daniel Wallace²⁴ and Ann Clarke⁴, ¹University of Waterloo, Burlington, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁷Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ⁸McGill University, Montréal, QC, Canada, ⁹Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Allegheny Health Network, Wexford, PA, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Northwestern University, Chicago, IL, ¹³CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁴Hanyang University Hospital, Seoul, Republic of Korea, ¹⁵Hanyang University Medical Center, Seoul, Republic of Korea, ¹⁶National University Health System (NUHS), Singapore, Singapore, ¹⁷National University of Singapore, Singapore, Singapore, ¹⁸Dalhousie University, Halifax, NS, Canada, ¹⁹Columbia University Medical Center, New York, NY, ²⁰Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ²¹Hospital Provincial de Rosario, Rosario, Argentina, ²²Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina, ²³University of Manchester, Manchester, United Kingdom, ²⁴Cedars-Sinai, Los Angeles, CA
Background/Purpose: The spread of COVID-19 misinformation through social/news media is a health risk in SLE. We assessed the determinants of SLE patients accessing health information…
Abstract Number: 1085 • ACR Convergence 2021
COVID 19 Infection in Patients with Rheumatic Immune-mediated Diseases in a Single University Hospital: Matched Case-control Study
David Martinez-Lopez¹, Diana Prieto-Peña¹, Lara Sánchez-Bilbao¹, Carmen Álvarez-Reguera¹, Alba Herrero-Morant¹, Fabricio Benavides-Villanueva¹, Cristina Corrales-Selaya¹, Martin Trigueros-Vazquez¹, Reinhard Wallmann², Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Cantabria Health Service, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: COVID19 may present different degrees of severity. It is generally thought that viral infections in patients with rheumatic inflammatory diseases (R-IMID) or receiving immunosuppressive…
Abstract Number: 1532 • ACR Convergence 2021
Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
Rebecca Haberman¹, Ramin Herati¹, David Simon², marie Samanovic¹, Michael Tuen¹, Rebecca Blank³, Sergei Koralov¹, Raja Atreya⁴, Koray Tascilar⁵, Joseph Allen¹, Rochelle Castillo⁶, Amber Cornelius¹, Paula Rackoff³, Gary Solomon⁷, Samrachana Adhikari¹, Natalie Azar⁸, Pamela Rosenthal⁹, Peter Izmirly¹⁰, Jonathan Samuels¹¹, Brian Golden¹², Soumya Reddy⁹, Markus Neurath⁴, Steven B. Abramson¹⁰, Georg Schett¹³, Mark Mulligan¹ and Jose Scher¹⁰, ¹NYU Grossman School of Medicine, New York, NY, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nrnberg, Erlangen, Germany, ³New York University, New York, NY, ⁴Deutsches Zentrum fur Immuntherapie, FAU Erlangen-Nuremberg and Universitatsklinikum Erlangen, Erlangen, Germany, ⁵Friedrich Alexander University of Erlangen Nuremberg, Universitaetsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology, Erlangen, Germany, ⁶NYU Langone Health, New York, NY, ⁷NYU Langone School of Medicine, Hartsdale, NY, ⁸NYU Langone, New York, NY, ⁹NYU School of Medicine, New York, NY, ¹⁰New York University School of Medicine, New York, NY, ¹¹NYU Langone, Rye Brook, NY, ¹²NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY, ¹³Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Patients with immune mediated inflammatory disorders (IMIDs) have an inherently heightened susceptibility to infection and may be considered high risk for developing COVID-19. While…
Abstract Number: 1550 • ACR Convergence 2021
Flares and Side Effects After COVID-19 Vaccination in Patients with Rheumatic Diseases
Anna Carbone, Gentiana Vukatana, Enrica Vandelli, Marica Trevisani, Elisa Rossi, Rita Mulè and Marco Fusconi, Rheumatology Unit, Azienda Ospedaliero-Universitaria Bologna, Bologna, Italy
Background/Purpose: There is increasing interest in the safety of COVID-19 vaccination in patients with underlying chronic conditions. We investigated the rates of side effects and/or…
Abstract Number: 1591 • ACR Convergence 2021
Impact of the COVID-19 Pandemic and Lockdown on Wellbeing on Patients with Rheumatic Diseases. Results from the REUMAVID Study (Phase 1)
Marco Garrido-Cumbrera¹, Helena Marzo-Ortega², Laura Christen³, José Correa-Fernández⁴, Sergio Sanz-Gomez⁴, Pedro Plazuelo-Ramos⁵, Laurent Grange⁶, Dale Webb⁷, Shantel Irwin⁸, Clare Jacklin⁹, Souzi Makri¹⁰, Elsa Frazão Mateus¹¹, Serena Mingolla¹², Katy Antonopoulou¹³ and Victoria Navarro-Compán¹⁴, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²NIHR Leeds Biomedical Research Centre and University of Leeds, Leeds, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁵Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁶French League Against Rheumatism (AFLAR), Echirolles, France, ⁷National Axial Spondyloarthritis Society (NASS), London, United Kingdom, ⁸Arthritis Action, London, United Kingdom, ⁹National Rheumatoid Arthritis Society (NRAS), London, United Kingdom, ¹⁰Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ¹¹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ¹²Italian National Association of People with Rheumatic and Rare Diseases (APMARR), Bari, Italy, ¹³Hellenic League Againts Rheumatism (ELEANA), Athens, Greece, ¹⁴Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain
Background/Purpose: The COVID-19 pandemic has impacted wellbeing of patients with Rheumatic and Musculoskeletal Diseases (RMDs). The aim is to assess wellbeing its associated factors in…
Abstract Number: 1608 • ACR Convergence 2021
Sources of Information About SARS-CoV-2 Used by Patients with Chronic Inflammatory Rheumatic Diseases (CIRD)
Ioana Andreica, Iulia Roman, Xenofon Baraliakos, Uta Kiltz and Juergen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRD) may be at increased risk of Corona Virus Disease 2019 (COVID-19).1 The quality of information obtained plays…
Abstract Number: 1843 • ACR Convergence 2021
Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
Jessica Gordon¹, Kimberly Showalter¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Richard Henry², Nora Østbø², Julia Nordlund², Angelica Bourgeault², Mara Canedo Ayala², Marie-Nicole Discepola², Andrea Carboni Jiménez², Christopher Denton⁵, Luc Mouthon⁶, Brett Thombs⁷ and Robert Spiera¹, ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁶Hopital Cochin - Paris University, Paris, France, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: Hesitancy about COVID-19 vaccination exists among patients with rheumatic and musculoskeletal diseases, but previous studies have not assessed this specifically in patients with systemic…
Abstract Number: 0003 • ACR Convergence 2021
Clinically Identifiable Autoreactivity Is Common in Severe SARS-CoV-2 Infection
Richard Ramonell¹, Matthew Woodruff², Mark Rudolph³, F. Eun-Hyung Lee¹ and Iñaki Sanz⁴, ¹Emory University, Atlanta, GA, ²Emory University, Decatur, GA, ³Exagen Inc., Vista, CA, ⁴Emory University School of Medicine, Atlanta, GA
Background/Purpose: A massive expanson of plasmablasts or antibody secreting cells (ASC) have been shown in severe patients with SARS-CoV-2 infection and in patients with autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].